IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer

Hirano, 1986, Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin, Nature, 324, 73, 10.1038/324073a0 Rose-John, 2004, IL-6 trans-signaling: the heat is on, Immunity, 20, 2, 10.1016/S1074-7613(04)00003-2 Hou, 2008, Roles of IL-6-gp130 signaling in vascular inflammation, Curr Cardiol Rev, 4, 179, 10.2174/157340308785160570 Jones, 2005, IL-6 transsignaling: the in vivo consequences, J Interferon Cytokine Res, 25, 241, 10.1089/jir.2005.25.241 Fielding, 2008, IL-6 regulates neutrophil trafficking during acute inflammation via STAT3, J Immunol, 181, 2189, 10.4049/jimmunol.181.3.2189 Hurst, 2001, Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation, Immunity, 14, 705, 10.1016/S1074-7613(01)00151-0 Teague, 1997, IL-6 rescues resting mouse T cells from apoptosis, J Immunol, 158, 5791, 10.4049/jimmunol.158.12.5791 Atreya, 2000, Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo, Nat Med, 6, 583, 10.1038/75068 Yoshida, 2010, Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells, Eur J Pharmacol, 634, 178, 10.1016/j.ejphar.2010.02.026 Rincon, 1997, Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells, J Exp Med, 185, 461, 10.1084/jem.185.3.461 Kimura, 2010, IL-6: regulator of Treg/Th17 balance, Eur J Immunol, 40, 1830, 10.1002/eji.201040391 Bettelli, 2006, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, 441, 235, 10.1038/nature04753 Mangan, 2006, Transforming growth factor-beta induces development of the T(H)17 lineage, Nature, 441, 231, 10.1038/nature04754 Veldhoen, 2006, TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells, Immunity, 24, 179, 10.1016/j.immuni.2006.01.001 Kimura, 2010, Th17 cells in inflammation, Int Immunopharmacol Chen, 2003, Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3, J Exp Med, 198, 1875, 10.1084/jem.20030152 Fantini, 2004, Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25− T cells through Foxp3 induction and down-regulation of Smad7, J Immunol, 172, 5149, 10.4049/jimmunol.172.9.5149 Fujimoto, 2011, The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells, J Immunol, 186, 32, 10.4049/jimmunol.0903314 Dominitzki, 2007, Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells, J Immunol, 179, 2041, 10.4049/jimmunol.179.4.2041 Jones, 2010, Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells, J Immunol, 184, 2130, 10.4049/jimmunol.0901528 Rabe, 2008, Transgenic blockade of interleukin 6 transsignaling abrogates inflammation, Blood, 111, 1021, 10.1182/blood-2007-07-102137 McLoughlin, 2005, IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation, Proc Natl Acad Sci USA, 102, 9589, 10.1073/pnas.0501794102 Ishihara, 2002, IL-6 in autoimmune disease and chronic inflammatory proliferative disease, Cytokine Growth Factor Rev, 13, 357, 10.1016/S1359-6101(02)00027-8 Yue, 2010, The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients, Rheumatol Int, 30, 1553, 10.1007/s00296-009-1179-x Swaak, 1988, Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases, Scand J Rheumatol, 17, 469, 10.3109/03009748809098809 Fujimoto, 2008, Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses, Arthritis Rheum, 58, 3710, 10.1002/art.24126 Liang, 2009, Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis, J Inflamm (Lond), 6, 10, 10.1186/1476-9255-6-10 Nowell, 2003, Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130, J Immunol, 171, 3202, 10.4049/jimmunol.171.6.3202 Lissilaa, 2010, Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity, J Immunol, 185, 5512, 10.4049/jimmunol.1002015 Nowell, 2009, Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis, J Immunol, 182, 613, 10.4049/jimmunol.182.1.613 Richards, 2006, Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis, Arthritis Rheum, 54, 1662, 10.1002/art.21818 Hashizume, 2008, IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17, Rheumatology (Oxford), 47, 1635, 10.1093/rheumatology/ken363 Nishimoto, 2007, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab, Ann Rheum Dis, 66, 1162, 10.1136/ard.2006.068064 Nishimoto, 2004, Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial, Arthritis Rheum, 50, 1761, 10.1002/art.20303 Emery, 2008, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial, Ann Rheum Dis, 67, 1516, 10.1136/ard.2008.092932 Vladic, 2002, Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients, Cytokine, 20, 86, 10.1006/cyto.2002.1984 Maimone, 1997, IL-6 detection in multiple sclerosis brain, J Neurol Sci, 146, 59, 10.1016/S0022-510X(96)00283-3 Patanella, 2010, Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients, J Neurosci Res, 88, 1106 Mendel, 1998, Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice, Eur J Immunol, 28, 1727, 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-# Okuda, 1998, IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein, Int Immunol, 10, 703, 10.1093/intimm/10.5.703 Samoilova, 1998, IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells, J Immunol, 161, 6480, 10.4049/jimmunol.161.12.6480 Eugster, 1998, IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis, Eur J Immunol, 28, 2178, 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D Eugster, 2001, Superantigen overcomes resistance of IL-6-deficient mice towards MOG-induced EAE by a TNFR1 controlled pathway, Eur J Immunol, 31, 2302, 10.1002/1521-4141(200108)31:8<2302::AID-IMMU2302>3.0.CO;2-# Linker, 2008, IL-6 transsignalling modulates the early effector phase of EAE and targets the blood–brain barrier, J Neuroimmunol, 205, 64, 10.1016/j.jneuroim.2008.09.007 Hirahara, 2010, Signal transduction pathways and transcriptional regulation in Th17 cell differentiation, Cytokine Growth Factor Rev, 21, 425, 10.1016/j.cytogfr.2010.10.006 Serada, 2008, IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis, Proc Natl Acad Sci USA, 105, 9041, 10.1073/pnas.0802218105 Wong, 2001, Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma, Clin Exp Immunol, 125, 177, 10.1046/j.1365-2249.2001.01602.x Morjaria, 2010, Sputum IL-6 concentrations in severe asthma and its relationship with FEV1, Thorax Dixon, 2008, Lower airway disease in asthmatics with and without rhinitis, Lung, 186, 361, 10.1007/s00408-008-9119-1 Doganci, 2005, Pathological role of IL-6 in the experimental allergic bronchial asthma in mice, Clin Rev Allergy Immunol, 28, 257, 10.1385/CRIAI:28:3:257 Tsuchiya, 2010, EGF receptor activation during allergic sensitization affects IL-6-induced T-cell influx to airways in a rat model of asthma, Eur J Immunol, 40, 1590, 10.1002/eji.200939907 DiCosmo, 1994, Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity, J Clin Invest, 94, 2028, 10.1172/JCI117556 Hausding, 2011, Induction of tolerogenic lung CD4+ T cells by local treatment with a pSTAT-3 and pSTAT-5 inhibitor ameliorated experimental allergic asthma, Int Immunol, 23, 1, 10.1093/intimm/dxq451 Doganci, 2005, The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo, J Clin Invest, 115, 313, 10.1172/JCI200522433 Wang, 2000, Endogenous and exogenous IL-6 inhibit aeroallergen-induced Th2 inflammation, J Immunol, 165, 4051, 10.4049/jimmunol.165.7.4051 Joetham, 2011, CD8 regulates T regulatory cell production of IL-6 and maintains their suppressive phenotype in allergic lung disease, J Immunol, 186, 113, 10.4049/jimmunol.1001663 Finotto, 2007, Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells, Int Immunol, 19, 685, 10.1093/intimm/dxm037 Dogan, 2006, Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children, Mediat Inflamm, 2006, 59206 Wedrychowicz, 2004, Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus, Exp Clin Endocrinol Diabetes, 112, 435, 10.1055/s-2004-821189 Galassetti, 2006, Effect of prior hyperglycemia on IL-6 responses to exercise in children with type 1 diabetes, Am J Physiol Endocrinol Metab, 290, E833, 10.1152/ajpendo.00445.2005 Gurr, 2002, A Reg family protein is overexpressed in islets from a patient with new-onset type 1 diabetes and acts as T-cell autoantigen in NOD mice, Diabetes, 51, 339, 10.2337/diabetes.51.2.339 Wu, 2010, The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes, Acta Diabetol, 10.1007/s00592-010-0198-0 Andriankaja, 2009, Levels of serum interleukin (IL)-6 and gingival crevicular fluid of IL-1beta and prostaglandin E(2) among non-smoking subjects with gingivitis and type 2 diabetes, J Periodontol, 80, 307, 10.1902/jop.2009.080385 Lagathu, 2003, Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone, Biochem Biophys Res Commun, 311, 372, 10.1016/j.bbrc.2003.10.013 Rotter, 2003, Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects, J Biol Chem, 278, 45777, 10.1074/jbc.M301977200 Bouma, 2005, NOD mice have a severely impaired ability to recruit leukocytes into sites of inflammation, Eur J Immunol, 35, 225, 10.1002/eji.200425513 Ansari, 2004, Modulation of diabetes with gonadotropin-releasing hormone antagonists in the nonobese mouse model of autoimmune diabetes, Endocrinology, 145, 337, 10.1210/en.2003-0512 Whetzel, 2006, Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor, Circ Res, 99, 731, 10.1161/01.RES.0000244088.33375.52 Pilstrom, 1995, Demonstration of a TH1 cytokine profile in the late phase of NOD insulitis, Cytokine, 7, 806, 10.1006/cyto.1995.0097 Teros, 2000, Cytokine balance and lipid antigen presentation in the NOD mouse pancreas during development of insulitis, Pancreas, 20, 191, 10.1097/00006676-200003000-00013 Campbell, 1994, Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice, Am J Pathol, 145, 157 Rabinovitch, 1998, An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus, Diabetes Metab Rev, 14, 129, 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V Hulbert, 2001, B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice, J Immunol, 167, 5535, 10.4049/jimmunol.167.10.5535 Waldner, 2006, Colon cancer and the immune system: the role of tumor invading T cells, World J Gastroenterol, 12, 7233, 10.3748/wjg.v12.i45.7233 Kiesslich, 2003, Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis, Gastroenterology, 124, 880, 10.1053/gast.2003.50146 Waldner, 2009, Colitis-associated cancer: the role of T cells in tumor development, Semin Immunopathol, 31, 249, 10.1007/s00281-009-0161-8 Mudter, 2007, Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications, Gut, 56, 293, 10.1136/gut.2005.090464 Neurath, 2009, Translating inflammatory bowel disease research into clinical medicine, Immunity, 31, 357, 10.1016/j.immuni.2009.08.016 Mudter, 2007, Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance, Inflamm Bowel Dis, 13, 1016, 10.1002/ibd.20148 Mitsuyama, 2006, Interleukin-6 trans-signaling in inflammatory bowel disease, Cytokine Growth Factor Rev, 17, 451, 10.1016/j.cytogfr.2006.09.003 Hyams, 1993, Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease, Gastroenterology, 104, 1285, 10.1016/0016-5085(93)90336-B Brown, 2002, Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients, Am J Gastroenterol, 97, 2603, 10.1111/j.1572-0241.2002.06030.x Umehara, 2006, Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis, Hepatogastroenterology, 53, 879 Louis, 1997, A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease, Eur J Gastroenterol Hepatol, 9, 939, 10.1097/00042737-199710000-00004 Holtkamp, 1995, Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease, J Clin Gastroenterol, 20, 123, 10.1097/00004836-199503000-00010 Reinisch, 1999, Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse, Am J Gastroenterol, 94, 2156, 10.1111/j.1572-0241.1999.01288.x Mitsuyama, 1995, Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6, Gut, 36, 45, 10.1136/gut.36.1.45 Yen, 2006, IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6, J Clin Invest, 116, 1310, 10.1172/JCI21404 Yamamoto, 2000, IL-6 is required for the development of Th1 cell-mediated murine colitis, J Immunol, 164, 4878, 10.4049/jimmunol.164.9.4878 Noguchi, 2007, Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner, Int Immunol, 19, 1431, 10.1093/intimm/dxm114 Leppkes, 2009, RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F, Gastroenterology, 136, 257, 10.1053/j.gastro.2008.10.018 Kitamura, 2004, Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis, J Leukoc Biol, 76, 1111, 10.1189/jlb.0604328 Kai, 2005, Colitis in mice lacking the common cytokine receptor gamma chain is mediated by IL-6-producing CD4+ T cells, Gastroenterology, 128, 922, 10.1053/j.gastro.2005.01.013 Hokama, 2004, Induced reactivity of intestinal CD4(+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation, Immunity, 20, 681, 10.1016/j.immuni.2004.05.009 Weigmann, 2008, The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis, J Exp Med, 205, 2099, 10.1084/jem.20072484 Mudter, 2008, The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6, J Clin Invest, 118, 2415 Ito, 2004, A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease, Gastroenterology, 126, 989, 10.1053/j.gastro.2004.01.012 Li, 2010, Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis, Gut, 59, 227, 10.1136/gut.2009.184176 Matsumoto, 2010, Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model, J Immunol, 184, 1543, 10.4049/jimmunol.0801217 Becker, 2004, TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling, Immunity, 21, 491, 10.1016/j.immuni.2004.07.020 Neufert, 2007, An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression, Nat Protoc, 2, 1998, 10.1038/nprot.2007.279 Becker, 2006, TGF-beta as a T cell regulator in colitis and colon cancer, Cytokine Growth Factor Rev, 17, 97, 10.1016/j.cytogfr.2005.09.004 Grivennikov, 2009, IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, Cancer Cell, 15, 103, 10.1016/j.ccr.2009.01.001 Neufert, 2010, Activation of epithelial STAT3 regulates intestinal homeostasis, Cell Cycle, 9, 652, 10.4161/cc.9.4.10615 Waldner, 2010, VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer, J Exp Med, 207, 2855, 10.1084/jem.20100438 Bollrath, 2009, gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis, Cancer Cell, 15, 91, 10.1016/j.ccr.2009.01.002 Hohki, 2010, Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses, Exp Eye Res, 91, 162, 10.1016/j.exer.2010.04.009 Neurath, 2002, The role of Th1/Th2 polarization in mucosal immunity, Nat Med, 8, 567, 10.1038/nm0602-567 Kishimoto, 2010, IL-6: from its discovery to clinical applications, Int Immunol, 22, 347, 10.1093/intimm/dxq030